法国ANRS药物警戒数据库中抗逆转录病毒药物宫内暴露与妊娠结局分析
基于法国ANRS药物警戒数据库2004-2019年34项研究918次分娩,评估产前抗逆转录病毒暴露与不良妊娠结局。以NNRTI方案为参照,除纯NRTI方案低出生体重风险升高(n=4,OR 7.50 [1.49-37.83])外,其他方案无显著关联;INI样本量过小无法结论。
要点
- 以NNRTI方案为参照,PI和INI方案未显示显著增加不良妊娠结局风险。
- 纯NRTI方案低出生体重风险升高(n=4,OR 7.50 [1.49-37.83]),但样本少需谨慎解读。
- INI方案暴露例数过少,无法得出可靠结论。
核心结论
- 整体上主要基于PI和NNRTI方案的研究对不良妊娠结局风险令人安心,但纯NRTI方案需谨慎解读(样本少、适应证偏倚)。
- INI方案例数过少,无法得出结论。
研究设计与样本
- 基于法国ANRS药物警戒数据库的 exhaustive 病例报告系列,纳入2004-2019年ANRS资助的HIV临床研究。
- 共34项研究、918次分娩,其中88%有妊娠结局记录。
主要发现
- 孕妇主要暴露于PI(n=387,48.6%)、NNRTI(n=331,41.5%)和INI方案(n=40,5.0%,其中18例使用多替拉韦)。
- 与NNRTI方案相比,其他方案暴露与自然流产、早产或低出生体重无显著关联。
- 纯NRTI方案暴露的新生儿低出生体重风险升高(n=4;OR 7.50 [1.49-37.83])。
关键数值与推荐
- 低出生体重定义:<2500 g;早产定义:<37周妊娠。
- 以NNRTI方案为参照,采用逻辑回归分别评估各结局的OR(结局发生>50例时)。
临床怎么用
- 临床对主要使用PI或NNRTI方案的孕妇可给予总体安心的妊娠结局风险信息。
- 纯NRTI方案与低出生体重关联需谨慎,避免过度解读,应结合个体情况评估。
- INI方案妊娠期暴露数据有限,决策时需考虑证据不确定性。
局限性
- 纯NRTI方案样本量小(n=4),存在适应证偏倚。
- INI方案暴露例数过少,无法得出可靠结论。
- 研究主要基于PI和NNRTI方案,其他方案代表性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In 2018, 1.07 million pregnant women received antiretroviral drugs, raising whether this affects pregnancy outcomes. We assessed the adverse pregnancy outcomes associated with prenatal antiretroviral drug exposure, notified to the French ANRS pharmacovigilance system. METHODS: An exhaustive case report series has been performed using the ANRS pharmacovigilance database. All ANRS-sponsored HIV clinical research studies using antiretroviral drugs either in pregnant women or women of childbearing age were eligible from 2004 to 2019. We analysed the following pregnancy outcomes: abortion, ectopic pregnancy, stillbirth, prematurity (<37 weeks of gestational age), low birth weight (<2500 g) and congenital abnormalities. A logistic regression was performed to assess the odds ratio (OR) for each outcome separately (if occurrence >50) compared to the outcome observed when exposed to non-nucleoside-reverse-transcriptase-inhibitor (NNRTI)-based regimen as the reference. RESULTS: Among the 34 studies selected, 918 deliveries occurred, of whom 88% had pregnancy outcomes documented. Pregnant women were mainly exposed to PI (n = 387, 48.6%), NNRTI (n = 331, 41.5%) and INI-based combinations (n = 40, 5.0%, 18 on dolutegravir). Compared to NNRTI-based combinations, there was no significant association observed with exposure to other antiretroviral combination for spontaneous abortion, prematurity or low birth weight, except an increased risk of low birth weight in new-born exposed to exclusive nucleoside-reverse-transcriptase-inhibitor (NRTI) combinations (n = 4; OR 7.50 [1.49-37.83]). CONCLUSIONS: Our study, mainly based on protease inhibitor (PI) and NNRTI-based regimens, is overall reassuring on the risk of adverse pregnancy outcomes, except for NRTI which should be interpreted cautiously (small number, indication bias). In this study, the number of integrase inhibitor (INI)-based combinations was too low to draw any conclusions.
引用
- Saint-Lary L, Diallo A, de Monteynard LA, et al. In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database. Br J Clin Pharmacol. 2021. PMID: 34505718. doi:10.1111/bcp.15075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。